drugset / Trial / NCT02721589
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, multiple centers, non-randomized, dose escalation phase I trial to evaluate safety and tolerability of SHR-1210 in patients with advanced solid tumors The primary objective is to assess safety and tolerability of SHR-1210 and identify recommended phase II doses of SHR-1210 in patients with advanced solid tumors
Timeline
- Start
- 2016-04-06
- Primary completion
- 2019-11-17
- Completion
- 2019-11-17
Publications
- Ma Y, Cao J, Zhang Y, Liu Q, Fang W, Yang Y, Zhao Y, Yang Q, Zhao H, Zhang L. Phase I study of camrelizumab in patients with advanced solid tumors. Signal Transduct Target Ther. 2023 Feb 1;8(1):47. doi: 10.1038/s41392-022-01213-6. No abstract available.
- Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, Zhang Y, Chen L, Zhou N, Zhao Y, Hou X, Yang Q, Zhang L. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018 Oct;19(10):1338-1350. doi: 10.1016/S1470-2045(18)30495-9. Epub 2018 Sep 10.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Camrelizumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Camrelizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |